ACM
AXSM icon

ACT Capital Management’s Axsome Therapeutics AXSM Stock Holding History

ACT Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$3.26M Buy
+73,000
New +$3.65M 4.5% 6
2021
Q3 		– Sell
-13,500
Closed -$911K – 112
2021
Q2 		$911K Buy
+13,500
New +$810K 0.47% 43

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

ACT Capital Management's AXSM Position: Q3 2022 in Review

ACT Capital Management opened a new position in Axsome Therapeutics (AXSM) in Q3 2022: 73,000 shares worth $3.26M. The stake represents 4.5% of the portfolio and ranks #6 among its holdings. This is a return to the name: ACT Capital Management previously reported a position in AXSM as recently as Q2 2021.

ACT Capital Management first reported a position in AXSM in Q2 2021 and has held it in 2 quarters since. 187 funds tracked by Wall St. Rank hold AXSM as of Q3 2022.

  • ACT Capital Management held 73,000 shares of Axsome Therapeutics worth $3.26M as of Q3 2022.
  • Axsome Therapeutics was a new ACT Capital Management position in Q3 2022.
  • Axsome Therapeutics made up 4.5% of ACT Capital Management's portfolio in Q3 2022, its #6 holding.
  • ACT Capital Management first reported a position in Axsome Therapeutics in Q2 2021 and has held it in 2 quarters since.
  • 187 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2022.

Based on ACT Capital Management's 13F filing for Q3 2022, filed 3 Nov 2022.